KR20170017388A - A composition comprising the stem of Schisandra chinensis for preventing or treating neurological disease - Google Patents
A composition comprising the stem of Schisandra chinensis for preventing or treating neurological disease Download PDFInfo
- Publication number
- KR20170017388A KR20170017388A KR1020150111231A KR20150111231A KR20170017388A KR 20170017388 A KR20170017388 A KR 20170017388A KR 1020150111231 A KR1020150111231 A KR 1020150111231A KR 20150111231 A KR20150111231 A KR 20150111231A KR 20170017388 A KR20170017388 A KR 20170017388A
- Authority
- KR
- South Korea
- Prior art keywords
- disease
- extract
- group
- neurological
- stem
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 27
- 208000025966 Neurological disease Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title description 20
- 240000006079 Schisandra chinensis Species 0.000 title description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 95
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims abstract description 36
- 230000036541 health Effects 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000023105 Huntington disease Diseases 0.000 claims description 25
- 208000018737 Parkinson disease Diseases 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000000926 neurological effect Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 230000002025 microglial effect Effects 0.000 abstract description 15
- 230000000324 neuroprotective effect Effects 0.000 abstract description 12
- 230000016273 neuron death Effects 0.000 abstract description 11
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 10
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 5
- 239000001384 succinic acid Substances 0.000 abstract description 5
- 210000005064 dopaminergic neuron Anatomy 0.000 abstract description 3
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 44
- 238000010171 animal model Methods 0.000 description 31
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 19
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 19
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 16
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 16
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 16
- 201000002491 encephalomyelitis Diseases 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 210000001577 neostriatum Anatomy 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 8
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 210000004498 neuroglial cell Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000000274 microglia Anatomy 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- -1 sizzindrin Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000013404 behavioral symptom Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YYNWDKOKDLIANV-UHFFFAOYSA-N 1-(1-methylcyclohexa-2,4-dien-1-yl)-3,6-dihydro-2h-pyridine Chemical compound C1CC=CCN1C1(C)CC=CC=C1 YYNWDKOKDLIANV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010048334 Mobility decreased Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 241001400472 Omiza Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 208000017376 neurovascular disease Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Abstract
The present invention relates to a pharmaceutical composition and a health functional food for preventing or treating a neurological disease, which comprises an extract of Omija stem.
The extract of Omija stem of the present invention inhibits neuronal cell death, increases activity of succinic acid dehydrogenase, inhibits microglial cell activity, increases dopaminergic neuron, It is useful as a pharmaceutical composition or a health functional food for preventing or treating neurological diseases since it has excellent neuroprotective effect.
Description
The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological diseases and a health functional food.
The central nervous system consists of neurons and glial cells. The glial cells are the most distributed cells in the brain, accounting for 90% of total brain cells and 50% of the total brain volume. These cells, by themselves, do not produce nerve impulses, but they are known to play a very important role in helping neurons perform their functions and to restore them when brain tissue is damaged. The glial cells are again composed of three kinds of astrocytes, microglia and oligodendrocytes.
Microglia, also called microglia or microglia, are immune cells in the central nervous system (CNS), accounting for 5-10% of total brain cells.
The microglial cells function as a primary defense line in the central nervous system. Microglia are the major intracellular sources of inflammation mediators in the central nervous system. Microglial cells are involved in nerve inflammation by producing nitric oxide (NO), reactive oxygen species (ROS), proinflammatory cytokines and prostaglandins. Activated microglial cells migrate to the damaged neural tissue area and predispose to and destroy microorganisms and cell debris.
However, the role of microglial cells as inflammatory cells is not always beneficial. Activation of uncontrolled microglial cells and persistent excessive neuroinflammation are thought to be the cause of various central nervous system pathologies, including neurodegenerative diseases. In other words, it is known that functionally activated microglial cells produce and secrete inflammatory mediators, resulting in neuronal cell death.
That is, microglial cells, which are immune cells present in the central nervous system, can be activated by various extrinsic and endogenous substances, and activated microglia can be activated by the inflammatory cytokines TNF-α and IL-1β, nitrogen monoxide, prostaglandins, Oxides, and other materials. The production of these substances induces an immune response in the short term, but its excessive production or sustained production induces the death of adjacent neurons, resulting in neurological diseases including neurodegeneration. In addition, neuronal degeneration becomes a vicious circle because the substances released by the dead neurons cause the microglial cells to re-activate. In fact, it has been reported that the activity of microglial cells is related to various neurological diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Lou Gehrig's disease, Creutzfelt-Jakob Disease (CJD) and multiple sclerosis.
Meanwhile, Schisandra chinensis ) is a fruit of Omija tree with a dark red color with a diameter of about 1 cm. It contains ingredients such as sizzindrin, glutamic acid, citrulline, malic acid and citric acid to strengthen the heart and lower the blood pressure, I write. It is known that it strengthens the pulmonary function, and it has the function of chinhae and geodam to help treat cough and thirst. It is also known to put dried fruits in cold water and add honey and sugar to the reddish water to drink it, or to make a bowl or starch piece.
However, only studies on the medicinal properties and efficacy related to Omija fruit have been conducted, and research on other medicinal parts such as Omija leaf and Omiza stem has not been conducted. In particular, considering that the fruit and the physiologically active substance of the leaf or stem are very different, and generally the omija is used only as a fruit, there is a need to research and develop other parts of the omija extract.
Under these circumstances, the present inventors completed the present invention by carrying out research and development on natural extracts effective for nervous system diseases.
It is an object of the present invention to provide a pharmaceutical composition for preventing or treating a neurological disease, which comprises an extract of Omija stem as an active ingredient.
It is also an object of the present invention to provide a health functional food for preventing or ameliorating a neurological disease, which comprises an extract of Omija stem as an active ingredient.
The inventors of the present invention have studied the effect of the stem extract of Omija, confirming that the extract of Omija stem has an action effect of reducing neuronal inflammation, inhibiting microglial cell activity, protecting neuronal cells, Respectively.
The present invention relates to a pharmaceutical composition for preventing and treating neurological diseases, which comprises Schizandra chinensis stem extract as an active ingredient.
The extract of Omija stem of the present invention inhibits neuronal cell death, increases activity of succinic acid dehydrogenase, inhibits microglial cell activity, increases dopaminergic neuron, And is useful as a pharmaceutical composition for the prevention or treatment of neurological diseases since it excellently protects neuronal cells.
In particular, the extract of Omija stem has a remarkable effect on the prevention and treatment of neurological diseases even in comparison with the fruit of Omija, and it has economic utility by using stem extract, which has not been used as medicinal or health functional food until now .
The Schizosaccharomyces stigma extract may be an extract extracted with water, alcohol or a mixed solvent thereof as an extraction solvent, and the alcohol may preferably be a C 1 to C 4 lower alcohol. Preferably, the Schizandra chinense extract of the present invention is a Schizandra chinensis hot water extract.
The neurological diseases include stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Pick disease, Creutzfeld- Jacob disease, frontotemporal dementia, dementia with Lewy bodies, amyotrophic lateral sclerosis, corticobasal degeneration, multiple system (multiple system) atrophy, progressive supranuclear palsy, neurological autoimmune disease, multiple sclerosis, inflammatory and neuropathic pain, neurovascular disease, and the like. And the like.
Preferably, the neurological disease is Huntington's disease, Parkinson's disease, multiple sclerosis.
In the production of the Schizandra chinensis extract, shaking extraction, Soxhlet extraction, or a reflux extraction method may be used, but the present invention is not limited thereto. The extraction temperature is preferably 40 to 100 ° C. The extraction time is preferably 0.5 to 24 hours, and the extraction time is preferably 1 to 5 times.
The extraction solvent used in the extraction may be water, alcohol or a mixture thereof. The alcohol is preferably a C 1 -C 4 lower alcohol, and methanol or ethanol may be used. The extraction solvent according to the present invention is most preferably extracted with water. In addition, it is preferable to add an extraction solvent having a weight or volume of 5 to 15 times the weight of the prepared Omija stem, and it is more preferable to perform extraction by adding 10 times.
The extract may be concentrated under reduced pressure, and it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator. Preferably, the extract is dried by vacuum drying, vacuum drying, boiling drying, spray drying or freeze drying. However, the present invention is not limited thereto.
The extract is preferably contained in an amount of 0.1 to 50% by weight based on the total weight of the composition containing the effective ingredient of the Schizosaccharomyces majore extract of the present invention, but is not limited thereto.
The composition of the present invention may be administered in various formulations, oral and parenteral, at the time of actual clinical administration. In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants which are usually used.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like. Such solid preparations can be prepared by incorporating into the pharmaceutical composition of the present invention at least one or more excipients such as starch, calcium carbonate, sucrose, Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium, stearide, and talc may also be used.
Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweeteners, fragrances and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. have.
Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like may be used as a base for suppositories. The pharmaceutical composition of the present invention can be administered by parenteral administration by subcutaneous injection, intravenous injection, or intramuscular injection.
The dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period, and can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at a dose of 0.1 to 1,000 mg / kg per day. The administration may be carried out once a day or divided into several doses. However, the scope of the present invention is not limited to these dosages.
The composition of the present invention can be used alone or in combination with methods for the prevention and treatment of neurological diseases or using surgery, hormone therapy, chemotherapy and biological response modifiers.
The present invention also provides a health functional food for preventing and ameliorating a neurological disease containing an extract of Omija stem as an active ingredient.
The health functional food of the present invention can be used as it is or in combination with other food or food ingredients, and can be suitably used according to conventional methods. The content of the active ingredient may be suitably determined according to the intended use (prevention, health or therapeutic treatment). In general, the complex extract of the present invention may be added in an amount of 0.01 to 15% by weight based on the total weight of the food during the manufacture of food or beverage.
There is no particular limitation on the kind of the food. Examples of the foods to which the compound extract of the present invention can be added include beverages, gums, vitamin complexes, and drinks, and include health functional foods in a conventional sense.
The health functional food of the present invention may be a health functional beverage, and the beverage may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Flavoring agents (saccharin, aspartame, etc.) other than those described above may also be used.
The health functional food of the present invention can be used as a nutritional supplement, a vitamin, a mineral (electrolyte), a flavor such as a synthetic flavor and a natural flavor, a colorant and an enhancer (cheese, chocolate etc.), a pectic acid and its salt, , Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
The extract of Omija stem of the present invention inhibits neuronal cell death, increases activity of succinic acid dehydrogenase, inhibits microglial cell activity, increases dopaminergic neuron, It is useful as a pharmaceutical composition or a health functional food for preventing or treating neurological diseases since it has excellent neuroprotective effect.
Figure 1 shows a classification according to Huntington's disease model induction and neurological behavior criteria using 3-nitropropionic acid (3-NP).
FIG. 2 shows the results of confirming the protective effect of Schizandra chinensis extract on neurological behavior and survival rate in a Huntington's disease model induced by 3-NP.
FIG. 3 shows the results of confirming the inhibitory effect of Omija stem extract on neuronal cell death in the Huntington's disease model induced by 3-NP.
FIG. 4 shows the results of confirming the recovery effect of Omija stem extract on inhibition of succinate dehydrogenase (SDH) in a Huntington's disease model induced by 3-NP.
FIG. 5 shows the results of confirming the inhibitory effect of Omija stem extract on microglial cell activation in a Huntington's disease-induced model induced by 3-NP.
Figure 6 shows the inhibitory effect of Omija stem extract on apoptosis in Huntington's disease model induced by 3-NP.
FIG. 7 shows an animal model of Parkinson's disease induced with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 1-Methyl- .
Fig. 8 shows the results of confirming the behavioral improvement effect of Schizandra chinensis extract treatment in an animal model of Parkinson's disease induced by MPTP.
FIG. 9 shows the results of confirming the neuroprotective effect of Omija stem extract by immunohistological examination in an animal model of Parkinson's disease induced by MPTP.
Figure 10 shows an animal model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein (MOG) peptides.
Fig. 11 shows the results of confirming the neuroprotective effect of Schizandra chinensis extract by behavioral examination in an animal model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein (MOG) peptides.
Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, the following examples should not be construed as limiting the scope of the present invention, but should be construed to facilitate understanding of the present invention.
Example 1. Stem of Schisandra chinensis ) ≪ / RTI >
200 g of dried omija stem (Dongro-myeon, Mungyeong-si, Gyeongbuk province) was placed in a reflux extractor together with 2.0 L of distilled water and allowed to stand for 1.5 hours, followed by heating and further heating for 1.5 hours from the start of boiling. The extract solution was filtered with a filter paper, filtered, concentrated using a vacuum decompression concentrator, and a powdery sample was prepared using a freeze dryer.
Example 2. Induction of 3-nitropropionic acid (3-NP) induction in Huntington's disease model
(1) Preparation of 3-NP induced Huntington's disease animal model
In an animal model of Huntington's disease, Huntington's disease animal models were prepared using 3-NP, a neurotoxic substance, in order to confirm the neuroprotective effect of Schizandra chinensis extract. Specifically, animal models were prepared by preparing male C57BL / 6 mice (Narabiotechnology, Korea) 8-9 weeks after birth and stabilizing for one week. 3-NP (Sigma, USA) was diluted in 100 μl of physiological saline and administered intraperitoneally over 4 times (60, 60, 80 and 80 mg / kg) at intervals of 12 hours.
The criteria for neurological behavior were classified as hind limb hindlimb, hindlimb muscle tension abnormality, activity, thoracic posterior hindlimb posture and postural change, and
(2) Protective effect of Schizandra chinensis extract on neurological behavior and survival rate in animal models of Huntington's disease
(75, 150, and 300 mg / kg) were diluted in physiological saline so that the dose per animal was 100 μl. After 5 days of induction of the Huntington's disease model, .
To confirm the neuroprotective effect of the Schizandra chinensis extract of the present invention on a Huntington's disease animal model, the experimental group was a control group (CON group); 3-NP group and 3-NP group without extract administration; 3-NP + animal model induced, 3-NP + extract (SSC) group; 3-NP, extract group, extract group; The extracts were divided into groups administered orally. In the experiments performed below, the administration of Omija stem extract was applied in the same manner.
After 24 hours of the last (4th) administration of 3-NP, the efficacy of the Schizandra chinensis extract against behavioral changes was verified using the criteria above for neurological behavior.
The results are shown in Fig. 2A. As shown in FIG. 2 A, the behavioral symptom of the 3-NP group was 8.8 ± 0.64, but the behavioral symptoms in the 3-NP + extract group were decreased dependently on the dose of the extract compared with that of the 3-NP group Especially in the group treated with 300 mg / kg. That is, 7.8 ± 0.55 in the 75 mg / kg extract group, 6.5 ± 0.86 in the 150 mg / kg group and 4.3 ± 0.77 in the 300 mg / kg group.
Further, the change in the survival rate was confirmed, and the results are shown in Fig. 2B. As shown in FIG. 2B, the survival rate of the 3-NP group was 50%, but the survival rate of the 3-NP + extract (SSC) group was significantly higher than that of the 3-NP group. That is, 81.3% in the 75 mg / kg extract group, 81.3% in the 150 mg / kg dose group and 75% in the 300 mg / kg dose group.
The change in body weight was also confirmed, and the results are shown in Fig. 2C. As can be seen in FIG. 2C, the body weight of the 3-NP group was 17 ± 0.43 g, which was significantly lower than that of the CON group, and the body weight of the 3-NP group was significantly increased to 19.4 ± 0.37 g in the 300 mg / kg extract group .
(3) Identification of the protective effect of Schizandra chinensis extract against neuronal cell death in Huntington's disease model
The mice were anesthetized by inhalation with ethyl ether 24 hours after the last (4th) administration of 3-NP, and the animals were anesthetized with phosphate buffer (pH: 4) containing 4% paraformaldehyde 7.4) was perfused through the heart and fixed, and the brain was harvested. The extracted brain was washed twice with phosphate buffered saline (PBS), immersed in 4% PFA and fixed at 4 ° C for one more day. Then, 10, 20 and 30% sucrose solution was added and stored at 4 ° C for 48 hours to prevent freezing damage. Using a freezing insert (Leica Cryostat CM3050S, Germany), the area containing the striatum (striatum) was corona-sectioned to a thickness of 30 μm and stored in PBS or freeze storage solution and stored in the freezer.
Cresyl violet staining was performed to determine the extent of 3-NP-induced neuronal death in the brain. That is, brain tissue was attached to a slide glass coated with gelatin and dried for 24 hours. The dried tissues were rehydrated with xylene and ethanol, stained with cresyl violet dye, sealed with a permount, and observed with an optical microscope.
The results are shown in Figs. 3A to 3E. Neurons were normally observed in the striae of the CON group (FIG. 3A), but neuronal death was pronounced in the striatum of the 3-NP group (FIG. 3B, dotted line). This neuronal death was markedly reduced in the 3-NP + extract group (SSC) (Fig. 3C-3E).
In order to quantitatively confirm these results, the percentage of brain with lesion indicating 3-NP-induced neuronal cell death was confirmed, and the result is shown in FIG. Kg in the group treated with 75 mg / kg of extract, 0 ± 0% in the group treated with 20 ± 0% and 300 mg / kg in the group treated with 150 mg / kg, 0 ± 0% %.
In addition, the area of a site where neuronal apoptosis occurred in relation to the area of a normal striatum was measured, and the result is shown in FIG. 3G. In the group treated with 75 mg / kg of extract (SSC), 27.3 ± 12.9%, in group treated with 150 mg / kg and 9.1 ± 5.8% in group 3-NP, 28 ± 7.6% Respectively.
In addition, Western blot experiments were performed to confirm the protective effect of 3-NP-induced neuronal cell death on the main protein levels of neurons. The mice were anesthetized with ethyl ether 24 hours after the last (4th) injection of 3-NP and the striatum of the cerebrum was extracted and the protein lysis buffer (50 mM Tris-cl, pH 7.5, 150 mM Nacl, 1% Triton X-100, 10% glycerol, and protease inhibitor mixture). Proteins of each individual were quantitated using Bradford (Bio-Rad, USA) method using bovine serum albumin (Sigma, USA) and then 30 μg of protein was resuspended in 10% SDS- PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred to a PVDF (polyvinylidene difluoride) membrane. PVDF membranes were blocked for 1 hour in TBS-T (Tris-buffered saline, 20 mM Tris, pH 7.4, 0.1
The results are shown in H and I in Fig. The protein expression of β-III-tubulin was consistent with the results of cresyl violet staining. It was confirmed that the expression of β-III-tubulin was increased by the administration of the extract.
(4) Huntington Disease In animal models, succinic acid dehydrogenase ( succinate dehydrogenase , SDH) inhibition of the extracts of Schizandra chinensis
3-NP was finally administered (fourth time), and after 24 hours, the mice were anesthetized by inhalation with ethyl ether and the cerebrum was extracted. The extracted cerebrum was frozen using an OCT compound, and then cut into a 5 ㎛ thick slice using a freezing machine and attached to a slide glass coated with gelatin, completely dried and stored in a freezer. To confirm whether the extract of Omija stem inhibits the decrease of the activity of succinic acid dehydrogenase by 3-NP, the tissue was added to SDH solution (mPMS, NBT, 0.24M disodium succinate stock, Azide / EDTA / PO4 buffer stock solution) Lt; / RTI > After dyeing, the cells were washed and dried. After xylene treatment, the cells were sealed with a perforated microscope and the activity of SDH was quantitated.
The results are shown in Fig. 4A to 4D show the result of staining, and E shows the result of quantification. As shown in FIG. 4, the activity of SDH in the striatum of the 3-NP group was significantly reduced (92.6%) as compared with that of the CON group (100%), ), Respectively (97.9%). The extract alone did not significantly affect SDH activity.
(5) Confirmation of inhibitory effect of Schizandra chinensis extract on microglial cell activation in Huntington's disease animal model
The mice were anesthetized by the above method, fixed, and frozen sections were prepared 24 hours after the last (4th) administration of 3-NP, and the Iba- Immunostaining was performed using an antibody against 1 (ionized calcium-binding adapter molecule-1; 1: 2,000, WAKO, Japan).
The results are shown in Fig. As shown in FIGS. 5A to 5H, the degree of immunoreactivity to Iba-1 in the striatum of the 3-NP group was significantly increased compared with that of the CON group, and the 3-NP + extract group (300 mg / kg) Respectively. In addition, the single administration of the extract did not significantly affect the immuno-positivity to Iba-1.
Western blot experiments were also performed and quantified by the method described above to determine whether the extract also affected protein expression on Iba-1.
The results are shown in I to J of Fig. As shown in I to J of Fig. 5, the degree of Iba-1 protein expression was consistent with the result of immunostaining.
(6) Confirmation of inhibitory effect of Omija stem extract on apoptosis in animal model of Huntington's disease
The mouse was anesthetized, fixed, and frozen sections were prepared by the above method 24 hours after the last (4th) administration of 3-NP. Immunization was performed using an antibody against clevead caspase-3, a marker of suicide cells Staining was performed.
The results are shown in Figs. 6A to H. In the 3-NP group, the level of immunopositive response to cleaved caspase-3 was significantly higher than that of the CON group and significantly decreased in the 3-NP + extract group (300 mg / kg). The extract alone did not significantly affect the immunopositive response to cleaved caspase-3.
Western blot experiments were also performed and quantified by the above method to determine whether the extracts also affect the protein expression of cleaved caspase-3.
The results are shown in I and J of Fig. The level of protein expression of cleaved caspase-3 was found to be decreased by the administration of Omija stem extract in accord with the results of immunostaining.
Example 3. 1- methyl Phenyl-1,2,3,6- Tetrahydropyridine ( MPTP ) Identification of treatment and prophylactic effects in an animal model of induced Parkinson's disease
(1) Production of MPTP-induced Parkinson's disease animal model
In order to confirm the neuroprotective effect of Omija stem extract on Parkinson 's disease animal model, Parkinson' s disease model was prepared using MPTP, a neurotoxic substance. Specifically, the animal model was prepared for 7 weeks after birth and male C57BL / 6 mice (Orient, Korea) were prepared and stabilized for one week. 100 [mu] l of MPTP in mice was diluted in physiological saline and administered intraperitoneally at a concentration of 20 mg / kg every 2 hours for 4 times to induce Parkinson's disease.
Oral extracts (37.5, 75, and 150 mg / kg) were diluted in physiological saline so that the dose per animal was 100 μl. After oral administration of the animal model for 5 days before the induction of the Parkinson's disease model, ≪ / RTI >
(2) MPTP Neuroprotective Effect of Schizandra chinensis Extract by Behavioral Test in Animal Model of Induced Parkinson's Disease
Rota-rod, pole and nest-building tests were performed on the mice 3-5 days after induction of MPTP-induced Parkinson's disease.
The Rotarod test was performed by placing the mouse on a rotatable cylindrical rod with a divider of 6 cm in diameter and operating at a speed of 15 rpm and then allowing the treadmill to rotate so that the time ) Was measured for a maximum of 5 minutes. The bottom has a sensor so that the time can be measured automatically when the mouse falls.
The pole test was carried out with a rod of 10 mm in diameter and 50 cm in height standing vertically, with the head of the mouse pointed up and placed on the end of the vertical bar for a maximum of 2 minutes.
In addition, a nesting test was conducted to examine the normal behavior of the mouse. Put a mouse in the cage and place a sheet of paper-like thick sheet (Nestlet, center) that can be torn. The mice were given enough time (18 hours) to tear the sheet and make it into a nest, and then divided into five grades. That is, the sheet is mostly torn but not identifiable (grade 3) (grade 1), tear to partial (50-90%) (grade 2) 3)), more than 90% of the sheet is torn and identified as a nest, but the nest of the plane (grade 4) and the nest in the form of a crater with more than 90% 5 (grade 5).
The experiment is shown in Fig. 7, wherein A in Fig. 7 represents the Rota Road inspection, B in Fig. 7 represents the pole inspection, and C in Fig. 7 represents the nesting inspection.
The experimental results are quantified and shown in FIG. 8A shows a rotor road inspection, FIG. 8B shows a pole inspection, and FIG. 8C shows a nesting inspection result.
As shown in FIG. 8A, rotavirus mobility decreased (168.7 sec) in the MPTP-treated group compared to the normal group (283.8 sec), and the MPTP and Omija stem extract-administered groups suppressed the concentration-dependent movement disorder (198.6 sec at 37.5 mg / kg, 209.7 sec at 75 mg / kg, 253.9 sec at 150 mg / kg).
As shown in Fig. 8B, when the vertical bar descent time was measured in the pole test, significant sweating was observed in the MPTP group (7.0 sec) compared to the normal group (5.2 sec). MPTP and Omija stem extracts improved the athletic performance decline (37.5 mg / kg for 6.2 seconds, 75 mg / kg for 5.7 seconds, and 150 mg / kg for 5.8 seconds).
As shown in Fig. 8C, the nesting test was performed (n = 2.5) in MPTP-treated group compared to the normal group (4.4 points). However, in the group treated with Omija stem extract, nesting behavior improved (2.8 points at 37.5 mg / kg, 3.4 points at 75 mg / kg, 4.0 points at 150 mg / kg).
(3) MPTP The neuroprotective effect of Omija stem extract on immunohistochemical examination in an animal model of induced Parkinson's disease
On the 7th day after induction of the animal model, mice were anesthetized with ethyl ether, perfused with 0.1 M phosphate buffer (pH 7.4) containing 4% paraformaldehyde (PFA) The brain was harvested. The extracted brain was washed twice with phosphate buffered saline (PBS), immersed in 4% PFA and fixed at 4 ° C for one more day. Then, 10, 20 and 30% sucrose solution was added and stored at 4 ° C for 48 hours to prevent freezing damage. Using a freezing insert (Leica Cryostat CM3050S, Germany), the sections containing the striatum and substantia nigra were coronal sectioned to a thickness of 30 μm and immersed in PBS or freeze storage solution, Lt; / RTI >
Striatum and black tissue were immersed in PBS containing 3% hydrogen peroxide for 20 minutes to remove the activity of endogenous peroxidase and washed with PBS. The tissues were immersed in blocking solution (5% normal goat / horse serum, 2% bovine serum albumin, 2% fetal bovine serum and 0.1% Triton X- The cells were reacted with a TH antibody (tyrosine hydroxylase; 1: 1,000; Millipore, USA) at 4 ° C for one day. Tissues were washed with PBS and reacted with secondary antibody (rabbit IgG; 1: 200; Vector, USA) at room temperature for 1 hour. After reaction with the secondary antibody, the cells were washed with PBS, reacted with ABC solution (Avidin Biotin Complex, Vector, USA) for 1 hour at room temperature, finally developed with DAB (diaminobenzidine) And then observed with a microscope.
The results are shown in Figs. 9A to 9J.
CON immunoreactive neurons were clearly observed in the dark part of the CON group, and the average was 147.7 ± 5.8 per tissue section, but the mean value was 83.8 ± 6.4 in the MPTP group and significantly decreased when compared to the CON group. However, TH immunoreactive neurons in the dark part of MPTP + extract group increased depending on the concentration of the extract. That is, 106.7 ± 12.3 in extract 37.5 mg / kg, 124.4 ± 6.5 in 75 mg / kg and 138 ± 6.6 in 150 mg / kg.
Further, the results obtained by normalizing the average intensity per tissue section to 100% and the quantitative values of the TH immunoreactive neuron are shown in K and L in Fig.
When the average intensity per tissue section was normalized to 100%, the TH immunoreactivity was clearly observed in the striae of the CON group, and the mean value was 41.6 ± 0.9% in the MPTP group, Respectively. However, in the striatum of the MPTP + extract group, the TH immunoreactivity was increased depending on the concentration of the extract. That is, 67.3 ± 4.5% in the extract group 37.5 mg / kg, 81.8 ± 2.7 in the 75 mg / kg group and 88.6 ± 2.8% in the 150 mg / kg group. The degree of TH immunoreactivity in the black and streaks of the extract group was in agreement with the normal group.
As previously noted, the quantitative level of TH immunoreactive neurons was confirmed, and it was confirmed that the level of TH immunoreactive neurons increased with the administration of Omija stem extract.
Example 4. Myelin Rare dendritic glial cell glycoprotein ( MOG , myelin oligodendrocyte glycoprotein ) Peptides Identification of treatment and prophylactic effects in animal model of induced multiple sclerosis
(One) Myelin Rare dendritic glial cell glycoprotein ( MOG , myelin oligodendrocyte glycoprotein ) Peptides Preparation of an animal model of induced multiple sclerosis
In order to confirm the neuroprotective effect of the Schizandra chinensis extract of the present invention on an animal model of multiple sclerosis, an animal model of experimental multiple sclerosis-related autoimmune encephalomyelitis (EAE) was prepared using MOG peptide. Specifically, animal models were prepared for 8 weeks after birth and female C57BL / 6 mice (Narabiotechnology, Korea) were prepared and stabilized for one week. Mice were mixed with an emulsion containing 200 ug of MOG peptide 35-55 (Sigma-Aldrich, USA) and IFA (Incomplete Freund's adjuvant; Difco, USA) containing 400 ug of mycobacterium tuberculosis (Difco, USA) And 0.1 ml of emulsion was injected subcutaneously into both waist regions of the EAE group and 200 ng of pertussis toxin (PTX, List Biologic, USA) was intraperitoneally injected. After 48 hours, the same amount of pertussis toxin was injected again into the abdominal cavity.
The clinical symptoms of the chronic EAE animal model induced by the MOG were classified into eight categories, which are shown in FIG. As shown in FIG. 10, there is no reaction (step 0), no tail end (step 1), a tail full step (step 2), weak paralysis of one hind limb (step 3), paralysis of both hind limbs (5), paralysis (6), and death (7).
(2) Myelin Rare dendritic glial cell glycoprotein ( MOG , myelin oligodendrocyte glycoprotein ) Peptides Neuroprotective efficacy of Schizandra chinensis extract by behavioral examination in an animal model of induced multiple sclerosis
To confirm neuroprotective efficacy against multiple sclerosis animal models of Omija stem extract, the experimental group consisted of CON group; Normal control without MOG peptide and extract, EAE group; MOG peptide, and EAE + extract group; EAE was induced by MOG peptide and the extract was divided into oral administration group.
EAE was induced by diluting Omija stem extract (37.5, 75 and 150 mg / kg) in physiological saline to give a dose of 100 μl per patient. After 30 days from the start of clinical symptoms (6-8 days) To the oral cavity.
The efficacy of the Schizandra chinensis extract against behavioral changes was checked using the above-mentioned clinical symptom scale for 30 days from the day when EAE of the mouse was induced, and the results are shown in FIG. 11A shows the clinical score change by date, and FIG. 11B shows the sum of the clinical scores.
As can be seen in FIG. 11, the behavioral symptoms of the EAE group began to appear between days 7 and 8 after EAE induction, reaching a peak (3.75) between 15 and 17 days, and continued thereafter. The sum of the scores from day 8 to
Preparation Example 1. Preparation of medicines
1.1 Manufacture of Powder
The above components are mixed and filled in airtight bags to prepare powders.
1.2 Preparation of tablets
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
1.3 Preparation of capsules
The above components are mixed according to a conventional capsule preparation method and filled into gelatin capsules to prepare tablets.
1.4 Manufacture of liquids
Purified water was added to make a total of 1,00 ml. The above components are mixed according to a usual method for producing a liquid agent, and then filled in a brown bottle and sterilized to prepare a liquid agent.
Formulation Example 2. Preparation of Health Functional Foods
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a component suitable for a health functional food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above components may be mixed And then used in the manufacture of a health functional food composition (for example, a nutritious candy, etc.) by a conventional method.
Formulation Example 3. Preparation of Health Functional Drink
The above components were mixed according to a conventional health functional beverage manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, It is used in the manufacture of the health functional beverage composition of the invention.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150111231A KR101860401B1 (en) | 2015-08-06 | 2015-08-06 | A composition comprising the stem of Schisandra chinensis for preventing or treating neurological disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150111231A KR101860401B1 (en) | 2015-08-06 | 2015-08-06 | A composition comprising the stem of Schisandra chinensis for preventing or treating neurological disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170017388A true KR20170017388A (en) | 2017-02-15 |
| KR101860401B1 KR101860401B1 (en) | 2018-05-23 |
Family
ID=58111759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150111231A KR101860401B1 (en) | 2015-08-06 | 2015-08-06 | A composition comprising the stem of Schisandra chinensis for preventing or treating neurological disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101860401B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107625849A (en) * | 2017-11-09 | 2018-01-26 | 山西中医药大学 | The purposes of wuzi yanzong pills |
| KR20190107388A (en) * | 2018-03-12 | 2019-09-20 | 경희대학교 산학협력단 | A composition comprising Micrandilactone C for preventing or treating neurological disease |
| KR20200110921A (en) | 2019-03-18 | 2020-09-28 | 주식회사 케이오씨바이오텍 | Composition for improving meat quality comprising extract of Schisandra chinensis by-product containing stem as an active ingredient and method for producing the same |
| KR20210040020A (en) | 2019-03-18 | 2021-04-12 | 주식회사 케이오씨바이오텍 | Composition for improving meat quality comprising extract of Schisandra chinensis stem as an active ingredient and method for producing the same |
| KR20210064532A (en) * | 2019-11-26 | 2021-06-03 | (주)큐엘바이오 | Composition for improving cognitive function, memory and activity comprising mixture of Schizandra chinensis extract and ascorbic acid as effective component |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040067771A (en) | 2003-01-17 | 2004-07-30 | 가부시키가이샤 히타치세이사쿠쇼 | Information recording and reproducing apparatus |
| KR20120086959A (en) | 2011-01-27 | 2012-08-06 | 엘지전자 주식회사 | Solar cell panel |
-
2015
- 2015-08-06 KR KR1020150111231A patent/KR101860401B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040067771A (en) | 2003-01-17 | 2004-07-30 | 가부시키가이샤 히타치세이사쿠쇼 | Information recording and reproducing apparatus |
| KR20120086959A (en) | 2011-01-27 | 2012-08-06 | 엘지전자 주식회사 | Solar cell panel |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107625849A (en) * | 2017-11-09 | 2018-01-26 | 山西中医药大学 | The purposes of wuzi yanzong pills |
| CN107625849B (en) * | 2017-11-09 | 2021-06-08 | 山西中医药大学 | Application of Wuzi Yanzong pills |
| KR20190107388A (en) * | 2018-03-12 | 2019-09-20 | 경희대학교 산학협력단 | A composition comprising Micrandilactone C for preventing or treating neurological disease |
| KR20200110921A (en) | 2019-03-18 | 2020-09-28 | 주식회사 케이오씨바이오텍 | Composition for improving meat quality comprising extract of Schisandra chinensis by-product containing stem as an active ingredient and method for producing the same |
| KR20210040020A (en) | 2019-03-18 | 2021-04-12 | 주식회사 케이오씨바이오텍 | Composition for improving meat quality comprising extract of Schisandra chinensis stem as an active ingredient and method for producing the same |
| KR20210064532A (en) * | 2019-11-26 | 2021-06-03 | (주)큐엘바이오 | Composition for improving cognitive function, memory and activity comprising mixture of Schizandra chinensis extract and ascorbic acid as effective component |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101860401B1 (en) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101860401B1 (en) | A composition comprising the stem of Schisandra chinensis for preventing or treating neurological disease | |
| KR101498780B1 (en) | Composition for preventing or treating hangover | |
| US8084061B2 (en) | Body fat-reducing agent | |
| US20120052138A1 (en) | Composition comprising green tea extract | |
| EP2436388B1 (en) | Composition for increasing the bioavailability of saponin | |
| KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
| KR20150086982A (en) | Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis | |
| KR20200032772A (en) | Beverage composition for treating hangover comprising black ginseng extact | |
| KR20160147132A (en) | A composition comprising the Leaves of Schisandra chinensis for preventing or treating Parkinson's disease or neurodegenerative disease | |
| KR101324431B1 (en) | Composition effective for removing hangover | |
| KR102483300B1 (en) | Composition for improving muscle atrophy comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component | |
| JP3334725B2 (en) | Accelerator for reducing alcohol in the body, its metabolites and oral freshener | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| CN113164541B (en) | Composition for preventing, treating or improving male climacteric syndrome comprising Sambucus nigra extract as active ingredient | |
| KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
| KR102343245B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Chrysanthemum indicum L. oil extract as effective component | |
| KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| WO2006109996A1 (en) | Composition comprising the extract from melandryum firmum for improvement of liver function and treatment of liver diseases | |
| KR20100111088A (en) | Composition for preventing and treating diabetes mellitus or diabetic complications comprising extract of herbal combination | |
| JP2004173589A (en) | Food for ameliorating or preventing pollinosis | |
| KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
| KR102594107B1 (en) | Composition for antifatique or exercise performance comprising mixed extract of Atractylodes macrocephala and Agastache rugosa | |
| KR102281950B1 (en) | Composition for reducing toxicity containing corn silk extract | |
| KR102461868B1 (en) | Method for improving storage stability of capsosiphon fulvescens extract with hair growth promoting effect | |
| KR102500034B1 (en) | A composition comprising an extract of Thymus quinquecostatus Celak for treating and preventing hangover |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| GRNT | Written decision to grant |